Well-known pharmaceutical companies have been exposed to withdraw insulin product-related promotion posts. Is the shock wave coming?

On March 3, industry sources said, “From February 28, Eli Lilly China, 3SBio and its affiliates officially stopped cooperating to promote humerin series products and humerin pre-filled products.

It is understood that in 2017, Eli Lilly and 3SBio reached a strategic cooperation.

The cooperation of the two parties was very optimistic at the time by the senior management of 3SBio.

If the aforementioned news of the suspension of cooperation is true and Eli Lilly withdraws the product, the relevant sales team expanded by 3SBio for this purpose will undoubtedly be dissolved.

Decline in revenue from mature products

According to data, Eli Lilly's recombinant human insulin (trade name: humerin) is the world's first synthetic human insulin product and the world's first human medical product created by recombinant DNA technology.

Most of the insulins currently used on the market in China are second- and third-generation insulins, among which Eli Lilly’s Humelin is a second-generation insulin.

Even in 2017, when Eli Lilly and 3SBio signed a cooperation agreement, the global sales of Eli Lilly's Humulin was US$1.

Eli Lilly’s performance in the first half of 2020 also revealed that the company’s performance growth mainly depends on the cancer drug Cyramza, the type 2 diabetes drug Jardiance, the type 2 diabetes drug Trulicity, and the diabetes drug Basaglar insulin glargine.

Volume purchase shock wave

In response to the above-mentioned news, we provided evidence to Eli Lilly and 3SBio to support the relevant aspects mentioned in it.

On March 4, according to Sina Pharmaceutical's inquiry, the "Listed Drugs" column of 3SBio's official website still displayed information about the insulin product Humulin.

However, as soon as the above news came out, it still attracted the attention of many people in the industry.

Under domestic policies such as mass purchasing, the prices of diabetes products are becoming more and more "friendly to the people", especially for mature products.

In the early years, pharmacokinetics of insulin products were often exposed to bribe doctors.

In July 2020, the industry reported that biological products (including insulin) and Chinese patent medicines will also start mass procurement.

Regarding when insulin products will be included in the national centralized procurement, analysts previously said that it will be by the end of this year at the latest.

With the implementation of pharmaceutical policies such as mass procurement, medical insurance negotiations, and consistency evaluation, the structure of the pharmaceutical industry has undergone major adjustments, and the original sales promotion model of pharmaceutical companies is bound to disappear.